Palisade Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ingevity
NGVT
|
+$12.5M |
| 2 |
BEAT
BioTelemetry, Inc.
BEAT
|
+$9.4M |
| 3 |
AABA
Altaba Inc
AABA
|
+$8.97M |
| 4 |
Visa
V
|
+$8.04M |
| 5 |
Ametek
AME
|
+$6.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SIVB
SVB Financial Group
SIVB
|
+$21.4M |
| 2 |
Omega Healthcare
OHI
|
+$12.2M |
| 3 |
Raymond James Financial
RJF
|
+$10.6M |
| 4 |
PTC
PTC
|
+$10.6M |
| 5 |
Semtech
SMTC
|
+$10.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.71% |
| 2 | Financials | 12.64% |
| 3 | Industrials | 11.22% |
| 4 | Healthcare | 9.34% |
| 5 | Consumer Discretionary | 6.48% |
Similar funds
Palisade Capital Management's Q4 2017 Portfolio in Review
As of Q4 2017, Palisade Capital Management held 468 positions worth $2.95B, up 5.1% from $2.81B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Palisade Capital Management withdrew a net $515M in Q4 2017, closing 35 positions and reducing 108 holdings. Its most notable exit was Omega Healthcare, an estimated $12.2M position sold in full.
By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 13% a quarter earlier, followed by Financials and Industrials.
Against the trend, Palisade Capital Management opened a new position in Ingevity worth $12.2M.
- Palisade Capital Management's largest Q4 2017 buy was Ingevity: 172,880 shares worth $12.2M.
- Palisade Capital Management added most to Visa in Q4 2017, an estimated $8.04M increase.
- Palisade Capital Management's biggest Q4 2017 reduction was SVB Financial Group, cutting an estimated $21.4M.
- Palisade Capital Management fully exited Omega Healthcare in Q4 2017, selling an estimated $12.2M.
- Palisade Capital Management's ten largest holdings make up 12% of its $2.95B portfolio in Q4 2017.
- Palisade Capital Management opened 29 new positions and closed 35 in Q4 2017.
- Palisade Capital Management's portfolio value rose 5.1% quarter-over-quarter to $2.95B.
Based on Palisade Capital Management's 13F filing for Q4 2017, filed 9 Feb 2018.